The panelists provide their closing thoughts, highlighting their key takeaways from their discussion about updates in heart failure management.
This is a video synopsis/summary of a panel discussion involving Robert Groves, MD; Eugene E. Wright Jr, MD; Nancy Albert, PhD, CCNS, CCRN, CHFN, NE-BC, FAHA, FCCM, FHFSA, FAAN; Nihar Desai, MD, MPH; and Kelly Marie Axsom, MD.
In closing thoughts, Desai reiterates the urgency of maximizing guideline-directed medical therapy at every patient encounter to prevent hospitalizations. Albert emphasizes that knowledge must stay current as evidence rapidly evolves. Axsom advises using multidisciplinary teams to support patients with complex heart failure. Hospitalization is a sentinel event warranting intensified therapy. Wright stresses beginning optimized therapy early and not waiting for adverse events. Overall, the informative discussion highlights key priorities such as timely intensification of treatment, using multidisciplinary teams, and staying abreast of the latest evidence. The panelists thank the audience and reaffirm their commitment to advancing patient care through education and sharing expertise.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
Study Highlights Key RA-ILD Risk Factors, Urges Early Screening
November 20th 2024This recent study highlights key risk factors for rheumatoid arthritis–associated interstitial lung disease (RA-ILD), emphasizing the importance of early screening to improve diagnosis and patient outcomes.
Read More
Why Right Heart Catheterization Confirming PAH Diagnosis May Be Underperformed
November 20th 2024Professional guidelines say that when pulmonary arterial hypertension (PAH) is diagnosed, right heart catheterization should be performed, but a quarter of the time, it isn’t—so investigators set out to discover why.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
New PsA Data Highlight Long-Term Benefits of Bimekizumab
November 19th 2024A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active psoriatic arthritis (PsA).
Read More